Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025

Rhea-AI Summary

Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biopharmaceutical company specializing in metabolic and endocrine disorder therapies, has scheduled its first quarter 2025 financial results release for April 23, 2025, after market close.

The company will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss financial results and corporate updates. Participants can join via phone (U.S.: 844-850-0543; International: 412-317-5199) or through the company's website. A replay will be available until April 30, 2025, using access code #8779272.

News Market Reaction – VKTX

+1.44%

1 alert

+1.44% News Effect

On the day this news was published, VKTX gained 1.44%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Conference Call Scheduled for Wednesday, April 23 at 4:30 p.m. Eastern Time

SAN DIEGO, April 16, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the first quarter 2025 after the market close on Wednesday, April 23, 2025.

The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, April 23, 2025. To participate on the conference call, please dial (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until April 30, 2025, by dialing (877) 344-7529 from the U.S. or (412) 317-0088 from outside the U.S. and entering replay access code #8779272. Those interested in listening to the conference call live via the internet may do so by visiting the Webcasts page of Viking's website at http://ir.vikingtherapeutics.com/webcasts. An archive of the webcast will also be available on the Webcasts page of the company's website for 30 days.

About Viking Therapeutics, Inc. 

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. Data from a Phase 1 and a Phase 2 trial evaluating VK2735 (dosed subcutaneously) for metabolic disorders demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in a Phase 2 trial. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a recently completed Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders.  In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD).  In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, as compared to placebo.

For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-report-financial-results-for-first-quarter-2025-on-april-23-2025-302429383.html

SOURCE Viking Therapeutics, Inc.

FAQ

When will Viking Therapeutics (VKTX) release Q1 2025 earnings?

Viking Therapeutics will release Q1 2025 earnings on Wednesday, April 23, 2025, after market close.

How can investors join Viking Therapeutics (VKTX) Q1 2025 earnings call?

Investors can join by dialing (844) 850-0543 (U.S.) or (412) 317-5199 (International), or by visiting Viking's website at ir.vikingtherapeutics.com/webcasts.

How long will Viking Therapeutics (VKTX) Q1 2025 earnings call replay be available?

The earnings call replay will be available until April 30, 2025, accessible via phone or webcast archive on the company's website.

What is the replay access code for Viking Therapeutics (VKTX) Q1 2025 earnings call?

The replay access code is #8779272.